Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan 2;4(1):100373.
doi: 10.1016/j.xinn.2023.100373. eCollection 2023 Jan 30.

Development of allogeneic hematopoietic stem cell transplantation in 2022: Regenerating "Groot" to heal the world

Meng Lv  1   2 , Mengzhu Shen  1   2 , Xiaodong Mo  1   2   3
Affiliations
Review

Development of allogeneic hematopoietic stem cell transplantation in 2022: Regenerating "Groot" to heal the world

Meng Lv et al. Innovation (Camb). .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
The figure illustrates three key steps for donor hematopoietic stem cells (HSCs) to reconstitute in the recipient’s environment and cure patients (1) Promote harmony of engrafted HSCs “seeds” and recipient environment“soil". (2) Orchestrate the“adolescent” plant modes and cure the “growing pain”—refractory GvHD. (3) The reconstituted "Big Tree-Groot" refines its ability to cure patients by“boost” from CAR-T cells, MSCs, NK cells and CTL cells.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Chang Y.,J., Pei X.Y., Huang X.J. Haematopoietic stem-cell transplantation in China in the era of targeted therapies: current advances, challenges, and future directions. Lancet. Haematol. 2022;9:e919–e929. - PubMed
    1. Guo H., Li R., Wang M., et al. Multiomics analysis identifies SOCS1 as restraining T cell activation and preventing Graft-Versus-Host Disease. Adv. Sci. 2022;9:e2200978. - PMC - PubMed
    1. Mo X.D., Hong S.D., Zhao Y.L., et al. Basiliximab for steroid-refractory acute graft-versus-host disease: a real-world analysis. Am. J. Hematol. 2022;97:458–469. - PubMed
    1. Burgos da Silva M., Ponce D.M., Dai A., et al. Preservation of the fecal microbiome is associated with reduced severity of graft-versus-host disease. Blood. 2022;140:2385–2397. - PMC - PubMed
    1. Lu P., Liu Y., Yang J., et al. Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL/LBL: first-in-human phase 1 clinical trial. Blood. 2022;140:321–334. - PubMed

LinkOut - more resources